Tuesday, August 29, 2023
Phebra and the University of Wollongong have entered into a new six-year collaboration agreement. This collaboration aims to further advance promising research and development (R&D) endeavours, including clinical trials, focused on patented and targeted arsenic compounds.
This collaboration not only emphasises the creation of new drugs but also the local production and commercialisation of essential medical solutions. Moreover, this extended collaboration further indicates the progress and potential of the research, with the anticipation of moving the developed drug into human trials.
This extended collaboration underscores Phebra's commitment to addressing critical unmet medical needs and actively pursuing the development, local manufacturing, and commercialisation of essential products.Through its partnership with UOW, Phebra aims to introduce novel pharmaceuticals that cater to significant unmet medical requirements.
The recently developed molecule employs a precision targeting system for the controlled delivery of minute quantities of its active component, arsenic, exclusively to predetermined cancer cells.
This innovative approach aims to minimise the occurrence of unintended side effects in non-target cells, thus broadening the drug's therapeutic applicability to challenging-to-treat cancer types. Favourable results have been observed in the case of acute myeloid leukaemia (AML) and pancreatic cell lines, indicating promising outcomes for the drug.
